Merck KGaA seems poised to take off in the immuno-oncology realm, with several key drugs moving through its pipeline and the launch of a promising IO partnership with GlaxoSmithKline to develop and market its M7824 (bintrafusp alfa*) investigational immunotherapy. Get an inside look at key developments at Merck with this In Vivo interview with Luciano Rossetti, the company’s head of global research and development, as Rossetti discusses Merck’s immuno-oncology innovations, the GSK IO alliance, and how it all fits into the larger landscape for cancer drug development.